National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) for advanced renal cell carcinoma

Nivolumab (Opdivo®) is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Rapid Review

Commenced Completed Outcome
27/04/2016 16/05/2016 Full Pharmacoeconomic Evaluation Recommended


Pharmacoeconomic Evaluation

Commenced Completed Outcome
28/10/2016  28/03/2017 Reimbursement Not Recommended at the Submitted Price


The HSE has approved reimbursement following confidential price negotiations October 2017.